Literature DB >> 3920549

Amantadine in the treatment of refractory epilepsy in childhood: an open trial in 10 patients.

W D Shields, J L Lake, H T Chugani.   

Abstract

Amantadine HCl was given to 10 children with medically refractory seizures; other anticonvulsant medications were continued unchanged through the 12- to 16-week trial. Several patients noted improvement in control of myoclonic or atypical absence seizures. Tonic seizures were controlled in one patient, but worsened in another. Tonic-clonic and atonic seizures remained unchanged or worsened. Amantadine may be useful as an adjunctive anticonvulsant in some children with refractory atypical absence or myoclonic seizures.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3920549     DOI: 10.1212/wnl.35.4.579

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Pharmacokinetic considerations in the treatment of childhood epilepsy.

Authors:  Jamie T Gilman; Michael Duchowny; Ana E Campo
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 2.  Pathological laughing and crying : epidemiology, pathophysiology and treatment.

Authors:  Hal S Wortzel; Timothy J Oster; C Alan Anderson; David B Arciniegas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Use of intravenous immunoglobulins in drug-resistant epilepsy.

Authors:  A Fois; M Vascotto
Journal:  Childs Nerv Syst       Date:  1990-11       Impact factor: 1.475

4.  Amantadine for the Treatment of Refractory Absence Seizures in Children.

Authors:  Mini Sreedharan; Kalpana Devadathan; Habib K Pathan; Shiji Chalipat; Kunju P A Mohammed
Journal:  J Pediatr Neurosci       Date:  2018 Apr-Jun

Review 5.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.